©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 12-18, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.1218

Nanoparticle Facilitated Delivery of Gut Microbiome Modulators in Obesity and Diabetes Management: A Mini Review

Nambi Namusisi H.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

The gut microbiome plays a critical role in regulating host metabolism, and emerging evidence suggests that dysbiosis, or an imbalance in microbial composition, is a key factor in the pathogenesis of obesity and type 2 diabetes (T2D). Modulating the gut microbiome through dietary interventions, prebiotics, probiotics, and microbial metabolites has shown promise as a strategy for managing obesity and T2D. However, the therapeutic potential of microbiome modulation is often limited by the poor bioavailability and stability of bioactive compounds, as well as the challenges in precisely targeting the gut. Nanotechnology offers a solution by enabling the targeted delivery of microbiome modulators with improved stability, controlled release, and enhanced bioavailability. Nanoparticles can protect sensitive bioactive compounds from enzymatic degradation and facilitate their targeted release in the gut, thereby optimizing their effects on microbial populations and host metabolism. This review discusses the role of nanoparticles in enhancing the delivery of gut microbiome modulators, including prebiotics, probiotics, and microbial metabolites, for the management of obesity and T2D. Additionally, it explores the mechanisms of action, current applications, challenges, and future directions for nanoparticle-based gut microbiome therapies.
Keywords: gut microbiome, nanoparticles, obesity, type 2 diabetes, prebiotics, probiotics, targeted delivery

INTRODUCTION

The gut microbiome, composed of trillions of microorganisms, plays a central role in regulating various physiological processes, including digestion, immune function, and metabolism. Increasing evidence highlights its involvement in the regulation of energy balance, nutrient absorption, and fat storage, all of which are disrupted in metabolic diseases such as obesity and type 2 diabetes (T2D)[1–4]. Dysbiosis, or an imbalance in the gut microbial community, has been implicated in the development of insulin resistance, chronic low-grade inflammation, and altered fat metabolism, all of which contribute to the pathophysiology of obesity and T2D.

In obesity, the gut microbiome composition shifts toward an increased proportion of Firmicutes and a decreased proportion of Bacteroidetes, which is associated with greater energy harvest from the diet and increased adiposity[5–8,9-13]. These changes can also lead to an increased production of short-chain fatty acids (SCFAs), which are known to influence appetite regulation and glucose metabolism. Similarly, the dysbiosis observed in T2D is characterized by alterations in microbial diversity and a shift toward an inflammatory microbiome. Certain gut microbes can produce metabolites that influence insulin sensitivity, such as SCFAs, which have anti-inflammatory effects and improve glucose homeostasis[5, 7, 9, 10-18]. However, the composition of the microbiome in individuals with T2D often leads to reduced production of beneficial metabolites and an increase in pro-inflammatory signals that exacerbate insulin resistance.

Given the critical role of the gut microbiome in metabolic regulation, strategies that aim to restore microbial balance hold significant therapeutic potential for managing obesity and T2D. Such strategies include the use of prebiotics, probiotics, and microbial metabolites, which can modify the microbiome composition and its metabolic output. However, the challenge remains in delivering these compounds effectively to the gut, where they can exert their beneficial effects without being degraded by stomach acids or digestive enzymes [19-25].

ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

2. Nanoparticles for Targeted Delivery of Gut Microbiome Modulators

Nanotechnology offers a promising solution to the challenges of delivering microbiome-modulating agents to the gut. Nanoparticles can be engineered to encapsulate bioactive compounds, such as prebiotics, probiotics, and microbial metabolites, protecting them from degradation in the upper gastrointestinal tract and ensuring their targeted release in the gut. The size, surface properties, and composition of nanoparticles can be tailored to optimize their stability, bioavailability, and targeting ability[11, 12, 26-28].

One of the primary advantages of using nanoparticles is their ability to enhance the stability of bioactive compounds. Many of the compounds used to modulate the microbiome, such as live probiotics or bioactive prebiotics, are sensitive to stomach acids, bile salts, and digestive enzymes[13–15,29-34]. Nanoparticles can protect these compounds by encapsulating them in a biocompatible matrix, preventing premature degradation and ensuring that they reach the intestine intact. Furthermore, the controlled release of these compounds from nanoparticles in the intestinal environment allows for more sustained and targeted delivery[16, 17,35-37].

In addition to stability and protection, nanoparticles can be designed for targeted delivery to specific areas of the gastrointestinal tract. For example, nanoparticles can be functionalized with ligands or antibodies that recognize and bind to receptors on the intestinal epithelium, allowing for more efficient uptake and localized release[18, 19,38-45]. This targeted approach is particularly important for gut microbiome modulation, as different regions of the gut have distinct microbial populations and functions. By delivering microbiome modulators to specific areas, nanoparticles can help achieve more precise and effective therapeutic outcomes.

Nanoparticles can also improve the bioavailability of microbiome modulators. Prebiotics, probiotics, and microbial metabolites often have low bioavailability due to poor absorption in the gastrointestinal tract[20, 46-49]. Nanoparticles can enhance the solubility and permeability of these compounds, allowing for better absorption and more effective action on the gut microbiome. Moreover, the use of nanoparticles can reduce the need for high doses of these compounds, potentially reducing the risk of side effects and improving patient compliance[13, 15,50-56].

3. Nanoparticle-Facilitated Delivery of Prebiotics

Prebiotics are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial gut bacteria, such as Bifidobacteria and Lactobacilli[21–24,57-64]. They have been shown to promote gut health, improve insulin sensitivity, and modulate the gut-brain axis, making them an attractive option for managing obesity and T2D. However, the effectiveness of prebiotics is often limited by their poor stability and low bioavailability in the gastrointestinal tract[25, 26, 65-69].

Nanoparticles can enhance the delivery of prebiotics by protecting them from degradation in the stomach and small intestine. For example, polymeric nanoparticles can encapsulate prebiotics like inulin, fructooligosaccharides, or galacto-oligosaccharides, ensuring that they reach the colon, where they can be fermented by the gut microbiota[27–29,70-75]. Additionally, nanoparticles can be designed to release prebiotics in a controlled manner, ensuring that they exert their effects over a prolonged period. By enhancing the bioavailability and targeting of prebiotics, nanoparticles can improve their therapeutic efficacy in the context of obesity and T2D.

4. Nanoparticle-Facilitated Delivery of Probiotics

Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. They play a crucial role in maintaining a balanced gut microbiome, improving immune function, and promoting metabolic health[30,76-79]. However, the survival of probiotics in the harsh conditions of the gastrointestinal tract, including exposure to stomach acid and bile, remains a significant challenge. Furthermore, the delivery of probiotics to specific regions of the gut, where they can colonize and exert their beneficial effects, is often inefficient[30, 31, 80-85].

Nanoparticles offer a solution to these challenges by providing a protective barrier for probiotics, shielding them from degradation in the stomach and allowing them to reach the intestine intact. For example, lipid-based nanoparticles or chitosan-based nanoparticles can encapsulate probiotics, enhancing their stability and ensuring that they survive the gastrointestinal transit[32, 33,86-88]. Additionally, nanoparticles can be designed to release probiotics in a controlled manner, allowing for sustained colonization in the gut. Targeted delivery of probiotics using nanoparticles can also improve their localization to specific gut regions, such as the colon, where they can most effectively modulate the microbiome and improve metabolic health.

5. Nanoparticle-Facilitated Delivery of Microbial Metabolites

Microbial metabolites, such as short-chain fatty acids (SCFAs), bile acids, and other microbial byproducts, have profound effects on host metabolism and are key players in gut-brain and gut-liver communication[34, 35]. SCFAs, for example, are produced by the fermentation of fiber by gut bacteria and have been shown to enhance insulin sensitivity, reduce inflammation, and promote satiety. However, the therapeutic potential of these metabolites is often limited by their short half-life and low bioavailability[35].

Nanoparticles can enhance the delivery and stability of microbial metabolites, allowing for more effective modulation of host metabolism. For example, nanoparticles can encapsulate SCFAs such as acetate, propionate, and butyrate, protecting them from degradation and ensuring their targeted release in the gut[36]. This can help maintain optimal concentrations of SCFAs in the gastrointestinal tract, leading to sustained therapeutic

ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

effects on insulin sensitivity and glucose metabolism. Additionally, nanoparticles can be designed to release microbial metabolites in response to specific environmental cues, such as pH changes or the presence of certain enzymes, further enhancing their effectiveness in treating obesity and T2D[36].

6. Challenges and Future Directions

Despite the promising potential of nanoparticle-facilitated delivery of gut microbiome modulators, several challenges remain in translating these strategies from preclinical studies to clinical practice. One of the main challenges is ensuring the biocompatibility and safety of nanoparticles[37]. While nanoparticles can improve the bioavailability and stability of bioactive compounds, they must be carefully designed to avoid toxicity or unintended interactions with host tissues. Long-term safety studies are needed to assess the potential risks associated with repeated nanoparticle administration[37, 38].

Another challenge is the regulatory approval of nanoparticle-based therapies. The use of nanoparticles in the delivery of microbiome modulators is a relatively new field, and regulatory agencies have yet to establish comprehensive guidelines for the development and approval of such therapies. Standardized methods for evaluating the quality, safety, and efficacy of nanoparticle-based formulations are needed to facilitate their clinical translation[39].

Personalization of treatment is also a critical consideration. Obesity and T2D are heterogeneous conditions, and the gut microbiome varies greatly between individuals. The development of personalized nanotherapy strategies that take into account an individual's microbiome composition, metabolic status, and genetic predisposition could significantly improve the outcomes of nanoparticle-based microbiome modulation[40, 41].

Finally, scalability and cost remain significant barriers to the widespread use of nanoparticle-based therapies. The manufacturing process for nanoparticles can be complex and expensive, and large-scale production may present logistical challenges. Efforts to optimize production methods and reduce costs will be essential to make nanoparticle-facilitated delivery of gut microbiome modulators commercially viable.

CONCLUSION

Nanoparticle-facilitated delivery of gut microbiome modulators represents a promising strategy for the management of obesity and type 2 diabetes. By enhancing the stability, bioavailability, and targeted delivery of prebiotics, probiotics, and microbial metabolites, nanoparticles can optimize the therapeutic effects of microbiome modulation, improving insulin sensitivity, reducing inflammation, and promoting metabolic health. While significant challenges remain in terms of safety, regulatory approval, and cost, the potential for nanoparticle-based therapies to revolutionize obesity and diabetes management is substantial. With further advancements in nanotechnology and a better understanding of the microbiome, nanoparticle-facilitated delivery could become a cornerstone of personalized and effective treatments for metabolic diseases.

REFERENCES

1. An, R., Wilms, E., Gerritsen, J., Kim, H.K., Pérez, C.S., Besseling-van der Vaart, I., Jonkers, D.M.A.E., Rijkers, G.T., de Vos, W.M., Masclee, A.A.M., Zoetendal, E.G., Troost, F.J., Smidt, H.: Spatio-temporal dynamics of the human small intestinal microbiome and its response to a synbiotic. Gut Microbes. 16, 2350173. https://doi.org/10.1080/19490976.2024.2350173
2. Chou, S., Zhang, S., Guo, H., Chang, Y., Zhao, W., Mou, X.: Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome. Front. Microbiol. 13, (2022). https://doi.org/10.3389/fmicb.2022.879207
3. Gundogdu, A., Nalbantoglu, O.U.: The role of the Mediterranean diet in modulating the gut microbiome: A review of current evidence. Nutrition. 114, 112118 (2023). https://doi.org/10.1016/j.nut.2023.112118
4. Ugwu, O.P.-C., Okon, M.B., Alum, E.U., Ugwu, C.N., Anyanwu, E.G., Mariam, B., Ogenyi, F.C., Eze, V.H.U., Anyanwu, C.N., Ezeonwumelu, J.O.C., Egba, S.I., Uti, D.E., Onohuean, H., Aja, P.M., Ugwu, M.N.: Unveiling the therapeutic potential of the gut microbiota-brain axis: Novel insights and clinical applications in neurological disorders. Medicine (Baltimore). 104, e43542 (2025). https://doi.org/10.1097/MD.0000000000043542
5. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int. J. Mol. Sci. 25, 9715 (2024). https://doi.org/10.3390/ijms25179715
6. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
7. Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., Wang, G.: Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. MedComm. 6, e70168 (2025). https://doi.org/10.1002/mco2.70168
8. Alum, E.U.: Circadian nutrition and obesity: timing as a nutritional strategy. J. Health Popul. Nutr. 44, 367 (2025). https://doi.org/10.1186/s41043-025-01102-y
9. Uti, D.E., Ugwu, O.P.-C., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov. Oncol. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2

10. Vamanu, E., Rai, S.N.: The Link between Obesity, Microbiota Dysbiosis, and Neurodegenerative Pathogenesis. Diseases. 9, 45 (2021). https://doi.org/10.3390/diseases9030045
11. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
12. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0

13. Azimizonuzi, H., Ghayourvahdat, A., Ahmed, M.H., Kareem, R.A., Zrzor, A.J., Mansoor, A.S., Athab, Z.H., Kalavi, S.: A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis. Cancer Cell Int. 25, 26 (2025). https://doi.org/10.1186/s12935-024-03610-z
14. Barua, S., Mitragotri, S.: Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today. 9, 223–243 (2014). https://doi.org/10.1016/j.nantod.2014.04.008
15. Argenziano, M., Arpicco, S., Brusa, P., Cavalli, R., Chirio, D., Dosio, F., Gallarate, M., Peira, E., Stella, B., Ugazio, E.: Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research. Pharmaceutics. 13, 1538 (2021). https://doi.org/10.3390/pharmaceutics13101538
16. Ahmar, H.: Nonenzymatic Electrochemical Detection of Glucose Using Screen-Printed Electrode Modified with Pd–Au Nanoparticles Encapsulated on Dendrimer Grafted Multi-Wall Carbon Nanotubes. Curr. Appl. Sci. 2, 67–78 (2024). https://doi.org/10.22034/cas.2022.343533.1019
17. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
18. Chandra, P., Ruhela, M., Kumar, P., Porwal, M., Verma, A., Sharma, H., Sachan, N.: Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges. Curr. Pharm. Des. 31, 1939–1957 (2025). https://doi.org/10.2174/0113816128347722250109042022
19. Yusuf, A., Almotairy, A.R.Z., Henidi, H., Alshehri, O.Y., Aldughaim, M.S.: Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on Responses in Biological Systems. Polymers. 15, 1596 (2023). https://doi.org/10.3390/polym15071596
20. Li, W., Zhan, M., Wen, Y., Chen, Y., Zhang, Z., Wang, S., Tian, D., Tian, S.: Recent Progress of Oral Functional Nanomaterials for Intestinal Microbiota Regulation. Pharmaceutics. 16, 921 (2024). https://doi.org/10.3390/pharmaceutics16070921
21. Appanna, V.D.: Dysbiosis, Probiotics, and Prebiotics: In Diseases and Health. Hum. Microbes - Power Within. 81 (2018). https://doi.org/10.1007/978-981-10-7684-8_3
22. Ali, S., Hamayun, M., Siraj, M., Khan, S.A., Kim, H.-Y., Lee, B.: Recent advances in prebiotics: Classification, mechanisms, and health applications. Future Foods. 12, 100680 (2025). https://doi.org/10.1016/j.fufo.2025.100680
23. Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S.J., Berenjian, A., Ghasemi, Y.: Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 8, 92 (2019). https://doi.org/10.3390/foods8030092
24. Pandey, Kavita.R., Naik, Suresh.R., Vakil, Babu.V.: Probiotics, prebiotics and synbiotics- a review. J. Food Sci. Technol. 52, 7577–7587 (2015). https://doi.org/10.1007/s13197-015-1921-1
25. Smolinska, S., Popescu, F.-D., Zemelka-Wiacek, M.: A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity. J. Clin. Med. 14, 3673 (2025). https://doi.org/10.3390/jcm14113673
26. Polyphenols, the new frontiers of prebiotics. In: Advances in Food and Nutrition Research. pp. 35–89. Academic Press (2020)
27. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
28. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
29. Mohaghegh, N., Ahari, A., Buttles, C., Davani, S., Hoang, H., Huang, Q., Huang, Y., Hosseinpour, B., Abbasgholizadeh, R., Cottingham, A.L., Farhadi, N., Akbari, M., Kang, H., Khademhosseini, A., Jucaud, V., Pearson, R.M., Hassani Najafabadi, A.: Simvastatin-Loaded Polymeric Nanoparticles: Targeting Inflammatory Macrophages for Local Adipose Tissue Browning in Obesity Treatment. ACS Nano. 18, 27764–27781 (2024). https://doi.org/10.1021/acsnano.4c10742
30. Latif, A., Shehzad, A., Niazi, S., Zahid, A., Ashraf, W., Iqbal, M.W., Rehman, A., Riaz, T., Aadil, R.M., Khan, I.M., Özogul, F., Rocha, J.M., Esatbeyoglu, T., Korma, S.A.: Probiotics: mechanism of action, health

benefits and their application in food industries. Front. Microbiol. 14, (2023). https://doi.org/10.3389/fmicb.2023.1216674
31. Maftei, N.-M., Raileanu, C.R., Balta, A.A., Ambrose, L., Boev, M., Marin, D.B., Lisa, E.L.: The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties. Microorganisms. 12, 234 (2024). https://doi.org/10.3390/microorganisms12020234
32. Lopes, S.A., Roque-Borda, C.A., Duarte, J.L., Di Filippo, L.D., Borges Cardoso, V.M., Pavan, F.R., Chorilli, M., Meneguin, A.B.: Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease—An Overview. Pharmaceutics. 15, 2600 (2023). https://doi.org/10.3390/pharmaceutics15112600

33. Chen, A., Gong, Y., Wu, S., Du, Y., Liu, Z., Jiang, Y., Li, J., Miao, Y.-B.: Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics. J. Nanobiotechnology. 23, 72 (2025). https://doi.org/10.1186/s12951-025-03141-3
34. Aghara, H., Patel, M., Chadha, P., Parwani, K., Chaturvedi, R., Mandal, P.: Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches. Mediators Inflamm. 2025, 6733477 (2025). https://doi.org/10.1155/mi/6733477
35. Zeng, L., Qian, Y., Cui, X., Zhao, J., Ning, Z., Cha, J., Wang, K., Ge, C., Jia, J., Dou, T., Chen, H., Liu, L., Bao, Z., Jian, Z.: Immunomodulatory role of gut microbial metabolites: mechanistic insights and therapeutic frontiers. Front. Microbiol. 16, (2025). https://doi.org/10.3389/fmicb.2025.1675065
36. Zeng, L., Qian, Y., Cui, X., Zhao, J., Ning, Z., Cha, J., Wang, K., Ge, C., Jia, J., Dou, T., Chen, H., Liu, L., Bao, Z., Jian, Z.: Immunomodulatory role of gut microbial metabolites: mechanistic insights and therapeutic frontiers. Front. Microbiol. 16, 1675065 (2025). https://doi.org/10.3389/fmicb.2025.1675065
37. Lin, Z., Zhao, Z., Lin, X., Yang, Z., Wang, L., Xi, R., Long, D.: Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems. Drug Deliv. 32, 2544689. https://doi.org/10.1080/10717544.2025.2544689
38. Kamath, S., Ariaee, A., Abdelhafez, A., Asif, Z., Chan, N.S.L., Collins, K., Hunter, A., Joyce, P.: Microbiome-active drug delivery systems (MADDS): Leveraging microbial stimuli for controlled drug release. Adv. Drug Deliv. Rev. 227, 115720 (2025). https://doi.org/10.1016/j.addr.2025.115720
39. Lin, C., Huang, X., Xue, Y., Jiang, S., Chen, C., Liu, Y., Chen, K.: Advances in medical devices using nanomaterials and nanotechnology: Innovation and regulatory science. Bioact. Mater. 48, 353–369 (2025). https://doi.org/10.1016/j.bioactmat.2025.02.017
40. Aydin, Ö., Nieuwdorp, M., Gerdes, V.: The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. Curr. Diab. Rep. 18, 55 (2018). https://doi.org/10.1007/s11892-018-1020-6
41. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
42. Isaac Edyedu PMA, Ugwu OPC, Ugwu CN, Alum EU, et al. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. Medicine. 2025;104(7):e41381.
43. Alum EU, Ugwu OPC, Obeagu EI, et al. Nutritional care in diabetes mellitus: A comprehensive guide. Int J Innov Appl Res. 2023;11(12):16-25.
44. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OPC, Alum EU. Biomarkers of breast cancer: Overview. Int J Curr Res Biol Med. 2023;1:8-16.
45. Uti DE, Alum EU, Atangwho IJ, Ugwu OPC, et al. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: Advances in targeted delivery and precision therapeutics. J Nanobiotechnol. 2025;23:336.
46. Ugwu CN, Ugwu OPC, Alum EU, Eze VHU, Basajja M, Ugwu JN, Ogenyi FC, et al. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. Medicine. 2025;104(18):e42289.
47. Obeagu EI, Scott GY, Amekpor F, Ugwu OPC, Alum EU. COVID-19 infection and diabetes: A current issue. Int J Innov Appl Res. 2023;11(1):25-30.
48. Offor CE, Ugwu OPC, Alum EU. Anti-diabetic effect of ethanol leaf extract of *Allium sativum* on albino rats. Int J Pharm Med Sci. 2014;4(1):1-3.
49. Asogwa FC, Okechukwu PCU, Esther UA, Chinedu OE, Nzubechukwu E. Hygienic and sanitary assessment of street food vendors in selected towns of Enugu North District, Nigeria. Am-Eurasian J Sci Res. 2015;10(1):22-26.
50. Alum EU, Uti DE, Agah VM, Orji OU, Nkeiru N, et al. Physico-chemical and bacteriological analysis of water used for drinking and domestic purposes in Amaozara Ozizza, Afikpo North, Nigeria. Niger J Biochem Mol Biol. 2023;38(1):1-8.
51. Ugwu OPC, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine. 2024;103(19):e38088.

52. Ezekwe CI, Uzomba CR, Ugwu OPC. Effect of methanol extract of *Talinum triangulare* on hematology and liver parameters in rats. Glob J Biotechnol Biochem. 2013;8(2):51-60.
53. Alum EU, Inya JE, Ugwu OPC, Obeagu EI, Aloke C, Aja PM, Okpata MG, et al. Ethanolic leaf extract of *Datura stramonium* attenuates methotrexate-induced biochemical alterations in Wistar rats. RPS Pharmacol Rep. 2023;2(1):1-6.
54. Ugwu OPC, Erisa K, Inyangat R, Obeagu EI, et al. Indigenous medicinal plants for managing diabetes in Uganda: Ethnobotanical and pharmacotherapeutic insights. INOSR Exp Sci. 2023;12(2):214-224.
55. Alum EU, Aja W, Ugwu OPC. Vitamin composition of ethanol leaf and seed extracts of *Datura stramonium*. Avicenna J Med Biochem. 2023;11(1):92-97.
56. Ezenwaji CO, Alum EU, Ugwu OPC. Digital health in pandemic preparedness and response: Securing global health? Glob Health Action. 2024;17(1):2419694
57. Adonu CC, Ugwu OP, Bawa A, Ossai EC, Nwaka AC. Intrinsic blood coagulation studies in patients with diabetes and hypertension. Int J Pharm Med Bio Sci. 2013;2(2):36-45.
58. Offor CE, Ugwu PC, Okechukwu PM, Igwenyi IO. Proximate and phytochemical analyses of *Terminalia catappa* leaves. Eur J Appl Sci. 2015;7(1):9-11.
59. Enechi YS, Ugwu OC, Ugwu KK, Ugwu OPC, Omeh N. Evaluation of antinutrient levels of *Ceiba pentandra* leaves. IJRRPAS. 2013;3(3):394-400.
60. Alum EU, Uti DE, Ugwu OPC, Alum BN, Edeh FO, Ainebyoona C. Microbiota in cancer development and treatment. Discov Oncol. 2025;16(1):646.
61. Asogwa FC, Okoye COB, Ugwu OPC, Edwin N, Alum EU, Egwu CO. Phytochemistry and antimicrobial assay of *Jatropha curcas* extracts. Eur J Appl Sci. 2015;7(1):12-16.
62. Enechi OC, Oluka HI, Ugwu PCO. Acute toxicity and ameliorative properties of *Alstonia boonei* leaf extract on diabetic rats. Afr J Biotechnol. 2014;13(5).
63. Alum EU, Obeagu EI, Ugwu OPC. Enhancing water, sanitation, and hygiene for diarrhoea control and SDGs: A review. Medicine. 2024;103(38):e39578.
64. Odo CE, Nwodo OFC, Joshua PE, Ugwu OPC, Okonkwo CC. Anti-diarrhoeal effect of chloroform–methanol extract of *Persea americana* seeds in rats. J Pharm Res. 2013;6(3):331-335.
65. Ugwu OPC, Obeagu EI, Alum EU, Michael M, et al. Effect of ethanol leaf extract of *Chromolaena odorata* on hepatic markers in diabetic rats. IAA J Appl Sci. 2023;9(1):46-56.
66. Ibiam UA, Alum EU, Orji OU, Aja PM, Nwamaka EN, Ugwu OPC, et al. Anti-inflammatory effects of *Buchholzia coriacea* leaf extract in arthritic rats. Indo Am J Pharm Sci. 2018;5(7):6341-6357.
67. Obeagu EI, Obeagu GU, Odo EO, Alum EU. Nutritional approaches for enhancing immune competence in HIV-positive individuals. IDOSR J Appl Sci. 2024;9(1):40-50.
68. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: Gatekeeper of iron in malaria resistance. Newport Int J Res Med Sci. 2023;4(2):1-8.
69. Nyamboga TO, Ugwu OPC, Ugwu JN, et al. Biotechnological innovations in soil health management: a systematic review of integrating microbiome engineering, bioinformatics, and sustainable practices. Cogent Food Agric. 2025;11(1):2519811.
70. Madu ANB, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Ukaidi CUA. The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. Medicine. 2025;104(18):e42300.
71. Alum EU, Ugwu OPC. Beyond pregnancy: Understanding long-term implications of gestational diabetes mellitus. INOSR Sci Res. 2024;11(1):63-71.
72. Ugwu OPC, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and GC-MS analysis of ethanol root extract and fractions of *Sphenocentrum jollyanum*. RPS Pharmacol Pharm Rep. 2023;2(2):rqad007.
73. Eze VHU, Eze CE, Mbabazi A, Ugwu CN, Ugwu PO, Ogenyi CF, Ugwu JN, et al. Qualities and characteristics of a good scientific research writing: Step-by-step approaches. IAA J Appl Sci. 2023;9(2):71-76.
74. Igwenyi IO, Nchi PO, Okechukwu UPC, Igwenyi IP, Obasi DC, Edwin N. Nutritional potential of *Azadirachta indica* seeds. Indo Am J Pharm Sci. 2017;4(2):477-482.
75. Enechi OC, Oluka IH, Ugwu OPC, Omeh YS. Effect of ethanol leaf extract of *Alstonia boonei* on lipid profile of alloxan-induced diabetic rats. Afr J Biotechnol. 2013;24.
76. Ugwu OPC. Anti-malaria effect of ethanol extract of *Moringa oleifera* leaves on malaria-induced mice. University of Nigeria Nsukka; 2011:39.
77. Alum EU, Ugwu OPC, Obeagu EI. Nutritional interventions for cervical cancer patients: Beyond conventional therapies. J Cancer Res Cell Ther. 2024;8(1):1-6.
78. Obeagu EI, Obeagu GU. Advancements in immune augmentation strategies for HIV patients. IAA J Biol Sci. 2024;11(1):1-11.

79. Okechukwu PU, Nzubechukwu E, Ogbanshi ME, Ezeani N, Nworie MO. Effect of ethanol leaf extract of *Jatropha curcas* on chloroform-induced hepatotoxicity in albino rats. Glob J Biotech Biochem. 2015;10:11-15.
80. Ilozue NM, Ikezu UP, Okechukwu PCU. Antimicrobial and phytochemical screening of *Persea americana* seed extracts. IOSR J Pharm Biol Sci. 2014;9(2):23-25.
81. Onyeze R, Udeh SM, Akachi B, Ugwu OP. Isolation and characterization of fungi associated with spoilage of corn (*Zea mays*). Int J Pharm Med Biol Sci. 2013;2(3):86-91.
82. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: The gatekeeper of iron in malaria resistance. Newport Int J Res Med Sci. 2023;4:1-8.
83. Obeagu EI, Alum EU, Obeagu GU, Ugwu OPC. Prostate cancer: Review on risk factors. Eurasian Exp J Public Health. 2023;4(1):4-7.
84. Offor CE, Okaka ANC, Ogbugo SO, Egwu CO, Okechukwu PC. Effects of ethanol leaf extract of *Pterocarpus santalinoides* on haemoglobin, packed cell volume and platelets. IOSR J Nurs Health Sci. 2015;4:108-112, 93.
85. Offor C, Aja PC, Ugwu O, Agbafor KN. Effects of ethanol leaf extract of *Gmelina arborea* on serum proteins in albino rats. Glob J Environ Res. 2015;9(1):1-4.
86. Alum EU, Uti DE, Obeagu EI, Ugwu OPC, Alum BN. Cancer's psychosocial aspects: Impact on patient outcomes. Elite J Med. 2024;2(6):32-42.
87. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate variability and malaria transmission: Unravelling the complex relationship. INOSR Sci Res. 2024;11(2):16-22.
88. Alum EU, Obeagu EI, Ugwu OPC, Egba SI, EjimUti DE, Ukaidi CUA, et al. Confronting dual challenges: Substance abuse and HIV/AIDS. Elite J HIV. 2024;2(5):1-8.

CITE AS: Nambi Namusisi H. (2026). Nanoparticle Facilitated Delivery of Gut Microbiome Modulators in Obesity and Diabetes Management: A Mini Review. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES.
https://doi.org/10.59298/NIJRMS/2026/7.1.1218